Prevalence’s of Dyslipidemia in medication of Psychotic Disorders.

Main Article Content

Dr. Syed Zafar Abbas
Syed Razi Muhammad
Muhammad Ali
Iqbal Pathan

Abstract

Objective: The present study aimed to investigate the dyslipidemic effects of risperidone, clozapine, and
haloperidol while teaching first-episode schizophrenia.
Place and Time: The sample (n=340) was selected from the outpatient department of the Sir Cows Jee Jehangir Institute of Psychiatry Hyderabad (CJIP). The selected patients were randomly grouped (100 each) to receive
risperidone, clozapine and haloperidol and 40 were given placebo (multivitamin). This study was single blinded.
The duration of study was 3 months (April to June 2011)
Results: The Mean, Standard Deviation and SEM values of risperidone was in total cholesterol level 207.2 ±
44.90 , 4.49, in HDL level 40.1 ± 6.60, .660, in LDL level 154.3 ± 28.64, 2.86,. and in triglyceride level 179.7 ±
37.07 , 3.70, Chi-squire test was used to compare the total cholesterol of control group and cholesterol level after
risperidone 0.001 P value was<.005 highly significant
Conclusion: Patients with severe mental illnesses are at increased metabolic risk. Psychiatric medications can
increase metabolic risk. Treatment decisions have implications for metabolic risk and outcomes.
Key Words: Psychosis, Risperidone, Clozapine, Haloperidol, Placebo, Hyperlipidemia.

Downloads

Download data is not yet available.

Article Details

How to Cite
Dr. Syed Zafar Abbas, Syed Razi Muhammad, Muhammad Ali, & Iqbal Pathan. (2013). Prevalence’s of Dyslipidemia in medication of Psychotic Disorders. JMMC, 4(1), 3-6. https://doi.org/10.62118/jmmc.v4i1.325
Section
Original Article